|Articles|February 1, 2004
- BioPharm International-02-01-2004
- Volume 17
- Issue 2
Site Expansion - Regional Round-Up: Maryland
Regional Round-Up: Maryland
Advertisement
Population
5,458,137
Workforce
2,914,323
Unemployment rate
4.1%
Key cities and populations
Primary Metropolitan Statistical Areas:
Baltimore: 2,552,994;
Washington, DC-Maryland-Virginia-West Virginia: 4,923,153
Targeted industries
Very strong genomics, proteomics, drug discovery and biodefense industries; continued commitment to promoting R&D, biomanufacturing, and pharmaceutical presence; new emphasis on agricultural biotechnology as well as industrial and environmental bioapplications
Biopharm employment
More than 80,000 (half in private sector, half in government research/academia)
Academia and government affiliated with biopharm industry
National Institutes of Health
The Johns Hopkins University; University System of Maryland
US Army Medical Research Institute of Infectious Diseases, Fort Detrick
Edgewood Army Chemical and Biological Defense Command
Walter Reed Army Institute of Research
FDA
USDA
Primary business strengths
3rd largest US industry cluster; highest US concentration of bioscience educated workforce; competitive cost savings on East Coast operations; easy access to rail and air transportation; low personal income tax rate; low corporate income tax structure
Tax and other incentives
Multiple programs individually tailored to each business
BioClusters
Most of Marylands bioscience industry lies within a 30 mile (50 km) radius between the cities of Washington, DC, Frederick, MD, and Baltimore, MD; approximately two-thirds of this community is in Marylands Washington suburbs, and one-third is in the greater-Baltimore area
Future plans for biopharm growth
Baltimores growth is centered around two biotechnology park initiatives, one in East Baltimore near Johns Hopkins Hospital and the other at the University of Maryland-Baltimore
Expanding the number of biotech incubator facilities (already the highest in the US)
Recent research facility expansions in Montgomery County
State committment to biopharm industry growth
Specialized State industry-focus team in DBED for business development, strategic partnering, and financial investment services to outstanding companies.
Long-term State investments in R&D, biomanufacturing, BSL3 facilities, incubators, and a five-center UMD Biotechnology Institute
State-level contacts
MD Department of Business and Economic Development:
Regional-level contacts
MdBio, Inc., 301.228.2445:
C. Robert Eaton, president,
Articles in this issue
over 21 years ago
Editorial—BioPharm Reflects the Industryover 21 years ago
Site Expansion - Regional Round-Up: Virginiaover 21 years ago
Qualification of Raw Materials for Biopharmaceutical Useover 21 years ago
Outsourcing Report: Big Pharma Promises to Focus on Productivityover 21 years ago
Costing Issues in the Production of Biopharmaceuticalsover 21 years ago
Canada: On the Biopharmaceutical Fast Trackover 21 years ago
The State of Intellectual Property in Canada: Pending and SpendingNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5